Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
about
When to treat patients with relapsed follicular lymphoma.Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registryMaintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Follicular lymphomas and their transformation: Past and current research.BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: a NLCS and CIBMTR Analysis.Transformed follicular lymphoma.Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.Current prognostic and predictive factors in follicular lymphoma.The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma.
P2860
Q30238528-32DC4B95-41FF-402D-B475-4ED4A518C75EQ33664022-6FB62D44-5207-4107-87A7-E8B5A7BA887CQ36305803-0A0F5974-87C5-43CB-95E3-593C4B19085BQ39290214-27A6D396-4EE2-487A-BB89-EE6E86DD6395Q40313556-2C8F3113-435A-49EC-B023-7A1384356C79Q45875848-04CF1C68-F935-411A-A83A-9F7DB2CE1373Q47771789-B4AD1477-BE30-4269-828A-0CFE9209B97EQ47984316-6B706D5F-55C0-4F1B-B56B-E043CE7B1363Q48185856-D10F0D06-121D-4CA6-85A4-ECCB5B5AAC7FQ48274743-99042FB8-E5D4-46D4-9C54-30BA113F1167Q48280234-AC72E715-1578-4855-A40C-18B0DF96AACFQ48726057-49999AFA-3DDE-4601-9746-4CCF0E01669EQ50089414-B2106A19-1808-4E05-8E62-A17BD4E24FAEQ55026647-580FCCD3-E425-4521-9C08-59D6BFB2D9D6
P2860
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@en
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@nl
type
label
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@en
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@nl
prefLabel
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@en
Risk Factors and Outcomes for ...... emotherapy in the PRIMA Trial.
@nl
P2093
P50
P356
P1476
Risk Factors and Outcomes for ...... hemotherapy in the PRIMA Trial
@en
P2093
Christiane Mounier
Danielle Canioni
Dolores Caballero
Fritz Offner
Hervé Tilly
Jehan Dupuis
John Seymour
Marlton Paula
Nick Wickham
P304
P356
10.1200/JCO.2015.65.7163
P407
P50
P577
2016-06-13T00:00:00Z